There is an ever-expanding need for SARS-CoV-2 antivirals. A recent analysis suggests fluvoxamine may greatly reduce the risk of hospitalization in Covid patients.
New Analysis Shows Fluvoxamine Has The Potential To Reduce Covid-19 Hospitalizations By More Than 90%
